Hankyung.com introduces: Unmissable BFCM Deal on Amazon: Get EXTREME DUAL ARGININE PLUS, Free Shipping, and Subscribe & Save Options!
https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.jpgPhoto: 1,000mg x 120 Tablets, 2 Months Supply, Boost up Energy & Vitality for Men's Sports Performance SEOUL, South Korea, Nov. 19, 2024 /PRNewswire/ -- This Black Friday and Cyber Monday (BFCM) season, health and fitness enthusiasts can enjoy exclusive savings on EXTREME DUAL ARGININE PLUS, the premium supplement designed to boost workout performance and support overall wellness. Available...
TRACE International Releases the 2024 Bribery Risk Matrix
ANNAPOLIS, Md., Nov. 19, 2024 /PRNewswire/ -- TRACE, a non-profit international business association dedicated to anti-bribery, compliance, and good governance, has released the 2024 Bribery Risk Matrix, measuring business bribery risk in 194 jurisdictions. Originally published in 2014 to meet a need in the business community for more reliable information about bribery risk worldwide, the TRACE Matrix helps companies examine...
2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries
AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging their potential to expand access in underserved regions. While the Foundation's new analysis shows improvement by some pharmaceutical companies in distinct areas, overall, momentum has slowed since the 2022 Index that overlapped with the COVID-19 pandemic, and growing gaps...
Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~50% and ~55% respectively, in M337V Motor Neurons in response to a...
Xinhua Silk Road: Inheriting traditions while promoting innovation, Chinese pharmaceutical company contributes to TCM globalization
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With continuous advancement of the Belt and Road Initiative, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. has been actively promoting the globalization of traditional Chinese medicine (TCM) through both inheriting traditional assets and engaging in modern innovations. The company, based in southeast China's Fujian Province, has been making continuing efforts in recent years...
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD’s The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by...
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to support the Company's strategy of HBV functional cure in broader patient populations...
SiPH Collaborates with IBM to Enhance Pathology Information System with Computational Advances and AI to Support Patients in Thailand and ASEAN
BANGKOK, Nov. 19, 2024 /PRNewswire/ -- Siriraj Piyamaharajkarun Hospital (SiPH), operating under Faculty of Medicine Siriraj Hospital, today announced a successful transformation of its Pathology Information System (PIS) using advanced computational technologies and artificial intelligence. In collaboration with IBM (NYSE: IBM), the system now integrates laboratory workflows, image scanning systems, and centralized...
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a highly conserved serine/threonine protein kinase that plays a crucial role during cellular mitosis. It is overexpressed in various...
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted TAHO's proposal for a 505(b)(2) NDA submission, based on a single pivotal bioequivalence...
Beyond Living Unveils Malaysia’s First Non Wearable AI-Driven SOS Device
KUALA LUMPUR, Malaysia, Nov. 19, 2024 /PRNewswire/ -- Proudly Malaysian-born, Beyond Living introduces the AI SOS Device, Malaysia's first non-wearable, AI-powered life-saving solution. The device is tailored to meet the needs of active lifestyle athletes, elderly, adults living alone and individuals with heart concerns, filling a critical gap in the health tech market. Co-founders Justin and Victor have leveraged their...
